https://www.selleckchem.com/pr....oducts/abtl-0812.htm
To determine whether neoadjuvant chemotherapy (NACT) disproportionately benefits obese patients. Data were collected from stage IIIC-IV ovarian cancer patients treated between 01/2010-07/2015. We performed univariate/multivariate logistic regression analyses with post-operative infection, readmission, any postoperative complication, and time to chemotherapy as outcomes. An interaction term was included in models, to determine if the effect of NACT on post-operative complications was influenced by obesity status. Of 507 patients, 115 (
Like
Comment
Share
